Zwanzig Jahre Levosimendan

Zusammenfassung

Vasopressoren kommen besonders in kritischen, nicht selten lebensbedrohlichen Situationen der Anästhesie, Notfall- und Intensivmedizin zum Einsatz. Die Wahl der geeigneten Substanz sowie die Erkennung und Beherrschung möglicher Nebenwirkungen sind von großer Bedeutung. Im folgenden Beitrag sollen daher die klinisch wichtigsten Substanzen vorgestellt und deren pharmakologische Charakteristika beleuchtet werden.

Abstract

Levosimendan is a calcium sensitizer and opens adenosine triphosphate-dependent potassium channels. Since 20 years, it is approved for acute decompensated heart failure. It has been tested in many clinical trials for treatment of at-risk patients in cardiac surgery, right ventricular failure, pulmonary hypertension, weaning of extracorporeal systems, cardiogenic shock, septic shock, ARDS and others.

Levosimendan has diverse positive effects next to positive inotropy. It improves ventriculoarterial coupling, increases peripheral perfusion, increases kidney glomerular filtration rate, coronary blood flow and it reduces preload and afterload as well as pulmonary capillary wedge pressure.

Due to the opening of potassium channels, it also acts on mitochondria resulting in organ protection. Levosimendan acts anti-apoptotic. These positive effects were described in many small studies. Although this sounds like a promising drug for a variety of settings, results of several multicentre randomized placebo-controlled studies were frustrating. This review resumes some facts of levosimendan in different diseases.

Kernaussagen

• Levosimendan wird empfohlen für Patienten mit akuter Herzinsuffizienz bei Hypotension und Hypoperfusion.

• Levosimendan hat keine Indikation beim septischen Schock.

• Die repetitive Gabe von Levosimendan bei der terminalen Herzinsuffizienz zeigt einen verbesserten Krankheitsverlauf. Dies konnte jedoch in Studien noch nicht belegt werden.

• Die Bolusinjektion von Levosimendan kann eine langanhaltende Hypotonie herbeiführen und sollte streng abgewogen werden.

• Levosimendan könnte bei Patienten mit eingeschränkter EF nach Bypassoperation ohne Klappenintervention von Vorteil sein.

Schlüsselwörter

Levosimendan - Herzinsuffizienz - Kardiochirurgie - Inotropie - Sepsis

Key words

levosimendan - heart failure - cardiac surgery - inotropy - sepsis

Publikationsverlauf

Artikel online veröffentlicht:
29. Juni 2021

• Literatur

• 1 Cholley B, Caruba T, Grosjean S. et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: The LICORN randomized clinical trial. JAMA 2017; 318: 548-556 DOI: 10.1001/jama.2017.9973.
• 2 Mehta RH, Leimberger JD, van Diepen S. et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017; 376: 2032-2042 DOI: 10.1056/NEJMoa1616218.
• 3 Lim JY, Deo SV, Rababaʼh A. et al. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta-analysis. J Card Surg 2015; 30: 547-554 DOI: 10.1111/jocs.12562.
• 4 Mebazaa A, Nieminen MS, Packer M. et al. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883-1891 DOI: 10.1001/jama.297.17.1883.
• 5 Sorsa T, Heikkinen S, Abbott MB. et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001; 276: 9337-9343 DOI: 10.1074/jbc.M007484200.
• 6 Levijoki J, Pollesello P, Kaivola J. et al. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 2000; 32: 479-491 DOI: 10.1006/jmcc.1999.1093.
• 7 Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995; 27: 2155-2165 DOI: 10.1016/s0022-2828(95)91371-8.
• 8 Haikala H, Kaivola J, Nissinen E. et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859-1866 DOI: 10.1016/0022-2828(95)90009-8.
• 9 Cholley B, Levy B, Fellahi JL. et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care 2019; 23: 385 DOI: 10.1186/s13054-019-2674-4.
• 10 Yokoshiki H, Katsube Y, Sunagawa M. et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-259 DOI: 10.1016/s0014-2999(97)01108-4.
• 11 Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004; 68: 807-812 DOI: 10.1016/j.bcp.2004.05.018.
• 12 Felker GM, Benza RL, Chandler AB. et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003 DOI: 10.1016/s0735-1097(02)02968-6.
• 13 Tawfik MK, El-Kherbetawy MK, Makary S. Cardioprotective and anti-aggregatory effects of levosimendan on isoproterenol-induced myocardial injury in high-fat-fed rats involves modulation of PI3K/Akt/mTOR signaling pathway and inhibition of apoptosis: comparison to cilostazol. J Cardiovasc Pharmacol Ther 2018; 23: 456-471 DOI: 10.1177/1074248418763957.
• 14 Louhelainen M, Vahtola E, Kaheinen P. et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 2007; 150: 851-861 DOI: 10.1038/sj.bjp.0707157.
• 15 Tziakas DN, Chalikias GK, Hatzinikolaou HI. et al. Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Cardiovasc Drugs Ther 2005; 19: 399-402 DOI: 10.1007/s10557-005-5417-5.
• 16 Comin-Colet J, Manito N, Segovia-Cubero J. et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail 2018; 20: 1128-1136 DOI: 10.1002/ejhf.1145.
• 17 Altenberger J, Parissis JT, Costard-Jaeckle A. et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail 2014; 16: 898-906 DOI: 10.1002/ejhf.118.
• 18 Belletti A, Landoni G, Lomivorotov VV. et al. Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence. J Cardiothorac Vasc Anesth 2020; 34: 1023-1041 DOI: 10.1053/j.jvca.2019.10.017.
• 19 Mebazaa A, Nieminen MS, Filippatos GS. et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009; 11: 304-311 DOI: 10.1093/eurjhf/hfn045.
• 20 Bergh CH, Andersson B, Dahlstrom U. et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010; 12: 404-410 DOI: 10.1093/eurjhf/hfq032.
• 21 Jacky A, Rudiger A, Kruger B. et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery – a retrospective before-and-after study. J Cardiothorac Vasc Anesth 2018; 32: 2112-2119 DOI: 10.1053/j.jvca.2018.04.019.
• 22 Distelmaier K, Roth C, Schrutka L. et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth 2016; 117: 52-58 DOI: 10.1093/bja/aew151.
• 23 Hansen MS, Andersen A, Tolbod LP. et al. Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure. Pulm Circ 2018; 8: 2045893217743122 DOI: 10.1177/2045893217743122.
• 24 Qiu J, Jia L, Hao Y. et al. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis. Life Sci 2017; 184: 30-36 DOI: 10.1016/j.lfs.2017.07.001.
• 25 Fang M, Cao H, Wang Z. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis. Med Intensiva 2018; 42: 409-415 DOI: 10.1016/j.medin.2017.08.009.
• 26 Landoni G, Lomivorotov VV, Alvaro G. et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med 2017; 376: 2021-2031 DOI: 10.1056/NEJMoa1616325.
• 27 Antcliffe DB, Santhakumaran S, Orme RML. et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med 2019; 45: 1392-1400 DOI: 10.1007/s00134-019-05731-w.
• 28 Follath F, Cleland JG, Just H. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202 DOI: 10.1016/s0140-6736(02)09455-2.
• 29 Moiseyev VS, Poder P, Andrejevs N. et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432 DOI: 10.1053/euhj.2001.3158.
• 30 Packer M, Colucci W, Fisher L. et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1: 103-111 DOI: 10.1016/j.jchf.2012.12.004.
• 31 Polzl G, Allipour Birgani S, Comin-Colet J. et al. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Fail 2019; 6: 174-181 DOI: 10.1002/ehf2.12366.